Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 601–700 of 911

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
Aboshi, M., Kaneko, M., & Narukawa, M. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1617-3 · Cited by 8
Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection
Okuma, Y., Yanagisawa, N., Takagi, Y., Hosomi, Y., Suganuma, A., Imamura, A., Iguchi, M., Okamura, T., Ajisawa, A., & Shibuya, M. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0316-1 · Cited by 8
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: A randomized, phase-II study
Kusagaya, H., Inui, N., Karayama, M., Nakamura, Y., Kuroishi, S., Yokomura, K., Toyoshima, M., Shirai, T., Masuda, M., Yamada, T., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.106 · Cited by 8
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question
Galetta, D., Rossi, A., Pisconti, S., Millaku, A., & Colucci, G. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70017-7 · Cited by 8
Management of Non-Small Cell Lung in Cancer Patients with Stable Disease
Grossi, F. (2012) · Drugs · doi:10.2165/1163013-s0-000000000-00000 · Cited by 8
Treatment of Advanced Lung Cancer in the Elderly
Gajra, A., & Lichtman, S. M. (2011) · Hospital Practice · doi:10.3810/hp.2011.04.400 · Cited by 8
Targeted therapy for NSCLC: ALK inhibition
Pearson, R., & Kolesar, J. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211417477 · Cited by 8
The place of pemetrexed in the management of non-small-cell lung cancer patients
Tomasini, P., Greillier, L., Khobta, N., & Barlési, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.171 · Cited by 8
Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy
Inui, N. (2017) · Medical Oncology · doi:10.1007/s12032-017-0937-y · Cited by 8
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
Chen, C., Chen, K., Shih, J., & Yu, C. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.12.007 · Cited by 8
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum
Xie, F., Zhao, P., Kou, J., Hong, W., Fu, L., Hu, L. T., Hong, D., Su, D., Gao, Y., & Zhang, Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1849-3 · Cited by 8
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy
Benešová, L., Pešek, M., Belšánová, B., Sekerka, P., & Minárik, M. (2010) · Journal of Separation Science · doi:10.1002/jssc.201000124 · Cited by 8
Tumor‐Targeted Superantigens
Hedlund, G., Forsberg, G., Nederman, T., Sundstedt, A., Dahlberg, L., Tiensuu, M., & Nilsson, M. F. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch24 · Cited by 8
Gas Plasma Combination Therapies—Promises from Preclinical Oncology Research
Yu, L., Berner, J., Martinet, A., Freund, E., Singer, D., von Woedtke, T., Weltmann, K., Emmert, S., Clemen, R., & Bekeschus, S. (2025) · Antioxidants · doi:10.3390/antiox14091055 · Cited by 7
Erlotinib in patients with advanced lung squamous cell carcinoma
Chiang, C., Tsai, C., Chou, T., Chen, Y., Lai, S., Shih, J.-F., Chiu, C., & Lee, Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1997-5 · Cited by 8
Phosphorylation of eIF2α Suppresses Cisplatin-Induced A549 Cell Apoptosis via p38 Inhibition
Guo, L., Chen, R., Ma, N., Xiao, H., Chen, Y., Chen, F., Mei, J., Ding, F.-B., & Zhong, H. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1340 · Cited by 7
Treatment of elderly patients with stage IV non-small-cell lung cancer
Weiss, J. M., & Stinchcombe, T. E. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.173 · Cited by 7
Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer
Sugiyama, T., Hirose, T., Nakashima, M., Ishida, K., Oki, Y., Murata, Y., Kusumoto, S., Shirai, T., Yamaoka, T., Okuda, K., et al. (2011) · Oncology · doi:10.1159/000334430 · Cited by 7
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Aoki, T., Igawa, S., Furuya, N., Katagiri, M., Hisata, J., Tajiri, S., Hayama, N., Mineshita, M., Urano, T., Miyazawa, T., et al. (2012) · PubMed · Cited by 7
HIF-1α and mTOR – Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC
Kramer, B., Polit, M., Birk, R., Rotter, N., & Aderhold, C. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20075 · Cited by 7
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies
Jiang, M., Liu, C., Ding, D., Tian, H., & Yu, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.827050 · Cited by 7
Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan.
Jeong, T.-Y., Park, B.-K., Lee, Y.-W., Cho, C.-K., & Yoo, H.-S. (2010) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2010.11.03 · Cited by 7
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee, S. J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.020 · Cited by 7
Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC who Failed First-Line Treatment
Jin, Y., Sun, Y., Shi, X., Zhao, J., Shi, L., Hong, W., & Yu, X. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.015 · Cited by 7
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation
Murakami, S., Oshita, F., Sugiura, M., Kondo, T., Saito, H., & Yamada, K. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2061-1 · Cited by 7
Targeted Therapies for Thymic Malignancies
Girard, N. (2010) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2010.08.004 · Cited by 7
Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study
Crombag, M. B. S., Schultink, A. H. M. D. V., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0207-z · Cited by 7
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601)
Kanto Respiratory Disease Study Group, Komiyama, K., Kobayashi, K., Minezaki, S., Kotajima, F., Sutani, A., Kasai, T., Mori, K., Hoshi, E., Takayanagi, N., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.437 · Cited by 7
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)
Hata, A., Katakami, N., Fujita, S., Nanjo, S., Takeshita, J., Tanaka, K., Kaneda, T., Nishiyama, A., Nishimura, T., Nakagawa, A., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2755-2 · Cited by 7
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)
Álvarez-Fernández, C., Perez, Q., Ruiz-Echeverria, L., Rubí, D. R., Sánchez‐Lorenzo, L., Torres, W. L., Izquierdo-Manuel, M., Berros, J. P., Luque-Cabal, M., Jiménez‐Fonseca, P., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9992-1 · Cited by 7
Quality of Care of Patients with Non–Small-Cell Lung Cancer: A Report of a Performance Improvement Initiative
Hirsch, F. R., Jotte, R. M., Berry, C. A., Mencia, W. A., Stowell, S. A., & Gardner, A. J. (2014) · Cancer Control · doi:10.1177/107327481402100113 · Cited by 7
RICTOR polymorphisms Affect Efficiency of Platinum-Based Chemotherapy in Chinese Non-Small-Cell Lung Cancer Patients
Wang, S., Song, X., Li, X., Zhao, X., Chen, H., Wang, J., Wu, J., Gao, Z., Qian, J., Han, B., et al. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0070 · Cited by 7
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)
Kentepozidis, N. K., Economopoulou, P., Christophyllakis, C., Chelis, L., Polyzos, A., Vardakis, N., Koinis, F., Vamvakas, L., Katsaounis, P., Kalbakis, K., et al. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1532-y · Cited by 7
Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma
Xu, Y., Zhu, C. Y., Qian, W., & Zheng, M. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2255-8 · Cited by 7
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202
Kuyama, S., Ochi, N., Bessho, A., Hotta, K., Ikeda, G., Kishino, D., Kubo, T., Harada, D., Fujimoto, N., Nakanishi, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.010 · Cited by 7
Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report
Song, J., Yu, J. J., Ma, Z., & Lu, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.4093 · Cited by 7
Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit
Puisset, F., Bigay-Game, L., Paludetto, M., Martel, A., Perriat, S., Rabeau, A., Canonge, J. M., & Mazières, J. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4415-7 · Cited by 7
EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
Gorden, K. J., Mesbah, P., & Kolesar, J. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211408373 · Cited by 6
An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy
Zhang, R., Jia, M., Xu, Y., Qian, D., Wang, M., Zhu, M., Sun, M., Chang, J., & Wei, Q. (2017) · International Journal of Cancer · doi:10.1002/ijc.31153 · Cited by 6
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives
Petrella, F., Rimoldi, I., Facchetti, G., & Spaggiari, L. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1528234 · Cited by 6
Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer
Luo, W., Li, Y., Ye, F., Li, Q., Zhang, G., Li, J., & Li, X. (2021) · Medicine · doi:10.1097/md.0000000000027954 · Cited by 6
Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2
Schluckebier, L. F., Garay, O. U., Zukin, M., & Ferreira, C. G. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.015 · Cited by 6
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer
Nie, X., Cheng, G., Ai, B., & Zhang, S. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130381 · Cited by 6
How much platinum-based chemotherapy is enough in NSCLC?
Peters, S., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.212 · Cited by 6
A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In Vitro
Dinavahi, S. S., Rajagopalan, P., Sriram, D., Yogeeswari, P., & Viswanadha, S. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.057 · Cited by 6
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Karikios, D. J., & Boyer, M. J. (2012) · Clinical Investigation · doi:10.4155/cli.12.7 · Cited by 6
Other signalization targets
Girard, N. (2013) · Targeted Oncology · doi:10.1007/s11523-012-0246-5 · Cited by 7
Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer—A report of two cases
Ochi, N., Yamane, H., Yamagishi, T., & Takigawa, N. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.010 · Cited by 6
EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy
Kim, Y. H., Masago, K., Togashi, Y., Sakamori, Y., Okuda, C., Mio, T., & Mishima, M. (2011) · Oncology Letters · doi:10.3892/ol.2011.240 · Cited by 6
Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study
Jouveshomme, S., Canouï‐Poitrine, F., Thuaut, A. L., & Bastuji‐Garin, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0544-5 · Cited by 6
Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group
Califano, R., Griffiths, R., Lorigan, P. C., Ashcroft, L., Taylor, P. D., Burt, P. A., Lee, L. W., Chittalia, A., Harris, M., Finn, C. F., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.001 · Cited by 6
Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Blais, N., & Hirsh, V. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00177 · Cited by 6
Case 31-2011
Lanuti, M. D., Sequist, L. V. D., Sharma, A., & Mino-Kenudson, M. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmcpc1013930 · Cited by 6
Reducing the Cost of Cancer Care: How to Bend the Curve Downward
Smith, T. J., Hillner, B. E., & Kelly, R. J. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.183 · Cited by 6
Self-citation
[Treatment of Advanced Squamous Cell Lung Cancer].
Zhu, Y., Xing, P., & Li, J. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.10.10 · Cited by 6
Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction
Oskina, N. A., Oscorbin, I. P., Khrapov, E. A., Boyarskikh, U. A., Субботин, Д. В., Демидова, И. А., Имянитов, Е. Н., & Филипенко, М. Л. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0281-0 · Cited by 6
Problems involved in the clinical trials for non-small cell lung carcinoma
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.001 · Cited by 6
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy
Ouyang, W., Su, S., Ma, Z., Hu, Y., Lü, B., Li, Q., Geng, Y., & Li, H. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-147 · Cited by 6
Retraction Note to: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Liu, J., Sheng, Z., Zhang, Y., & Li, G. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0468-z · Cited by 6
Retracted
RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Liu, J., Sheng, Z., Zhang, Y., & Li, G. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0376-7 · Cited by 5
Retracted
Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
Børø, S., Thoresen, S., Brant, S. B., & Helland, Å. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2264484 · Cited by 5
Carboplatin and Gemcitabine in First-Line Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Data from a Retrospective Study
Genestreti, G., Giovannini, N., Frizziero, M., Maglie, M. D., Sanna, S., Cingarlini, S., Molino, A., Piciucchi, S., Cetto, G. L., & Santo, A. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.4.232 · Cited by 5
Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents
Berge, E. M., & Doebele, R. C. (2013) · Drugs · doi:10.1007/s40265-013-0032-4 · Cited by 5
2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment — First-line therapy
Gridelli, C., Rossi, A., & Maione, P. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70171-x · Cited by 5
Treatment, Rationale, and Study Design of TALISMAN Study: A Randomized Phase II Open-Label Study of Second-line Erlotinib Versus Intermittent Erlotinib Dosing With Docetaxel in the Treatment of Former-Smoker Men Affected by Recurrent Squamous Non–Small-Cell Lung Cancer
Gridelli, C., Rossi, A., Venturino, P., & de Marinis, F. (2011) · Clinical Lung Cancer · doi:10.3816/clc.2011.n.010 · Cited by 5
YXQ-EQ Induces Apoptosis and Inhibits Signaling Pathways Important for Metastasis in Non-Small Cell Lung Carcinoma Cells
Yan, X., Shen, H. M., Jiang, H., Hu, D., Wang, J., & Wu, X. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493223 · Cited by 5
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer
Kong, Y., Liang, H., Xu, X., & Xu, J. H. (2021) · Medicine · doi:10.1097/md.0000000000026862 · Cited by 5
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang, Y., Liu, Y., Zhou, J., Xu, N., Li, B., Wu, G., Fang, J., Li, K., Liu, X., Liu, W., et al. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.10.03 · Cited by 5
Frontline Systemic Therapy With Pemetrexed–Platinum in Nonsquamous Non–Small-Cell Lung Cancer With Asymptomatic Brain Metastases
Alsidawi, S., Chaudhary, R. T., & Karim, N. A. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000106 · Cited by 5
INTEGRATED CARE PATHWAYS IN LUNG CANCER: A QUALITY IMPROVEMENT PROJECT
Fasola, G., Menis, J., Follador, A., Carlo, E. D., Valent, F., Aresu, G., Pellegrin, A. D., Giacomuzzi, F., Iuri, D., Lugatti, E., et al. (2018) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646231700441x · Cited by 5
Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
Chen, Z., Shen, S., Shi, W., Jiang, G., Wang, X., Jian, H., Zhou, Z., Ding, Z., & Lü, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189287 · Cited by 5
Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma
Zhu, J., Zhou, R., & Xiao, H. (2019) · EXCLI journal · doi:10.17179/excli2019-1964 · Cited by 6
Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis
Yi, Y., Liu, Z., Fang, L., Li, J., Liu, W., Wang, F., Fu, P., Xie, C. L., Liu, J., & Song, B. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04091-3 · Cited by 5
Systemic Therapy for Mutation-Driven NSCLC
Sun, L., Marmarelis, M. E., & Langer, C. J. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.11.011 · Cited by 6
Maintenance therapy in non-small-cell lung cancer.
Schmid‐Bindert, G. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.10.02 · Cited by 5
Tumors of the Lung, Pleura, and Mediastinum
Rosenzweig, K. E., Chen, C. P., Yom, S. S., & Krug, L. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5897-7.00036-6 · Cited by 5
Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement
Akiba, J., Kawahara, A., Abe, H., Azuma, K., Yamaguchi, T., Taira, T., Fukumitsu, C., Takase, Y., Yasumoto, M., Umeno, Y., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2511 · Cited by 4
A Randomized Phase II Trial of Gemcitabine plus Carboplatin: Biweekly versus Standard Schedules in Patients with Advanced Non-Small Cell Lung Cancer
Hasegawa, Y., Miura, D., Kitamura, C., Suzuki, T., Kobayashi, K., & Sato, N. (2013) · Chemotherapy · doi:10.1159/000362222 · Cited by 4
Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer
Qi, H., Jiang, S., Yu, D. H., Ni, H., Hu, Q., & Zhang, J. (2015) · Medical Oncology · doi:10.1007/s12032-015-0704-x · Cited by 4
Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing
Snee, M. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.05.004 · Cited by 4
Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer
Guilleminault, L., Lemarié, É., & Heuzé‐Vourc'h, N. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.36153 · Cited by 4
The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor
Sheng, Z., & Zhang, Y. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000179 · Cited by 4
Modern Treatments in Advanced Non–Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study
Carpentier, O., Selvaggi, L., Jegu, J., Purohit, A., Prim, N., Velten, M., & Quoix, É. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.05.001 · Cited by 4
Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System
Dawe, D. E., & Ellis, P. M. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2030077 · Cited by 4
Patterns of Care for Non–Small-Cell Lung Cancer at an Academic Institution Affiliated With a National Cancer Institute–Designated Cancer Center
Nguyen, K.-S. H., Sanford, R. A., Huberman, M. S., Goldstein, M. A., McDonald, D. M., Farquhar, M. B., Gangadharan, S. P., Kent, M. S., Michaud, G. C., Majid, A., et al. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2011.000274 · Cited by 4
Social factors, treatment, and survival in patients with advanced-stage non-small cell lung cancer
Lazarus, M. A., Schachter, L. G., & Xavier, M. F. (2014) · Translational Cancer Research · doi:10.21037/2365 · Cited by 4
Budget impact analysis of pemetrexed introduction: case study from a teaching hospital perspective, Thailand.
Chanjaruporn, F., Roughead, E. E., Sooksriwong, C., & Kaojarern, S. (2011) · PubMed · Cited by 4
[Bevacizumab combined with chemotherapy for advanced non-small cell lung cancer: a meta-analysis].
Zhang, T., Yuan, S.-F., Wang, Z., Zhang, Q., Zhao, P., & Li, S. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.02.05 · Cited by 4
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases
Andreano, A., Valsecchi, M., Russo, A., & Siena, S. (2020) · Archives of Public Health · doi:10.1186/s13690-021-00528-0 · Cited by 5
Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non‐small‐cell lung cancer
Ryu, W., Kim, J. S., Park, M., Lee, M.-K., Kim, H.-J., Ryu, J., & Lim, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14207 · Cited by 4
Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy
Shintani, H., Oura, S., Yamaguchi, T., & Makimoto, S. (2021) · Case Reports in Oncology · doi:10.1159/000520473 · Cited by 4
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Zukin, M. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70190-2 · Cited by 4
Radiation Oncologists, Mortality, and Treatment Choices
Ellsworth, S. G., Smith, T. J., & Lutz, S. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.08.017 · Cited by 4
Self-citation
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)
Miyanaga, A., Kubota, K., Hosomi, Y., Okuma, Y., Minato, K., Fujimoto, S., Okamoto, H., Satouchi, M., Isobe, H., Aono, H., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz064 · Cited by 4
A network meta-analysis
Luo, H., Zheng, W., Yan, Q., Wang, B., Ye, B., Deng, S., He, F., Yang, X., & Wang, X. (2020) · Medicine · doi:10.1097/md.0000000000020500 · Cited by 4
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials
Jiang, J., Liang, X., Zhou, X., Huang, R., Chu, Z., & Zhan, Q. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0502-9 · Cited by 4
Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcítico
García‐Foncillas, J., Garrido, P., Gómez‐Román, J., Palacios, J., & Tarón, M. (2011) · Revista Española de Patología · doi:10.1016/j.patol.2011.02.003 · Cited by 4
Therapeutic vaccination for non-small-cell lung cancer: a meta-analysis
Ding, M., & Yang, J. (2014) · Medical Oncology · doi:10.1007/s12032-014-0928-1 · Cited by 4
Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer
Yazdi, M. T., Keene, K., Hiemstra, P., & van der Burg, S. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.862499 · Cited by 5
Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective
Bosch‐Barrera, J., MARGALL, N. Q., & Brunet, J. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.007 · Cited by 4

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks